$1.17 Billion is the total value of Palo Alto Investors LP's 29 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 15.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $195,162,580 | +16.5% | 1,885,811 | -4.6% | 16.64% | +25.6% |
| UTHR | Sell | UNITED THERAPEUTICS CORP | $173,921,379 | +31.1% | 625,414 | -1.3% | 14.83% | +41.4% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $128,128,346 | +24.6% | 10,493,722 | +6.6% | 10.92% | +34.4% |
| INSM | Buy | INSMED INC | $117,308,394 | -6.8% | 5,871,291 | +0.5% | 10.00% | +0.6% |
| BIIB | Buy | BIOGEN INC | $105,252,307 | +9.2% | 380,082 | +5.3% | 8.97% | +17.8% |
| PRTA | Buy | PROTHENA CORP PLC | $99,929,264 | -0.1% | 1,658,577 | +0.5% | 8.52% | +7.7% |
| RVNC | Buy | REVANCE THERAPEUTICS INC | $97,535,422 | -18.0% | 5,283,609 | +19.9% | 8.32% | -11.6% |
| STAA | Buy | STAAR SURGICAL CO | $60,193,338 | -22.2% | 1,240,077 | +13.1% | 5.13% | -16.1% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $37,831,794 | +37.8% | 2,376,369 | +41.6% | 3.23% | +48.6% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $32,667,558 | -2.0% | 856,517 | +0.6% | 2.78% | +5.7% |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $19,229,298 | -37.4% | 5,655,676 | +0.6% | 1.64% | -32.5% |
| ALKS | ALKERMES PLC | $15,766,842 | +17.0% | 603,400 | 0.0% | 1.34% | +26.2% | |
| ALGN | Buy | ALIGN TECHNOLOGY INC | $15,734,195 | +71.5% | 74,605 | +68.4% | 1.34% | +84.7% |
| SNDX | SYNDAX PHARMACEUTICALS INC | $15,590,670 | +5.9% | 612,600 | 0.0% | 1.33% | +14.2% | |
| ANAB | ANAPTYSBIO INC | $13,357,434 | +21.5% | 431,024 | 0.0% | 1.14% | +31.1% | |
| EHTH | Buy | EHEALTH INC | $12,024,878 | +55.5% | 2,484,479 | +25.6% | 1.02% | +67.5% |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $8,037,416 | -62.4% | 1,087,607 | -49.8% | 0.68% | -59.5% |
| CYTK | CYTOKINETICS INC | $5,118,873 | -5.4% | 111,717 | 0.0% | 0.44% | +1.9% | |
| KZR | KEZAR LIFE SCIENCES INC | $4,619,648 | -18.2% | 656,200 | 0.0% | 0.39% | -11.9% | |
| PRVB | PROVENTION BIO INC | $4,130,756 | +134.8% | 390,800 | 0.0% | 0.35% | +153.2% | |
| TVTX | TRAVERE THERAPEUTICS INC | $3,492,431 | -14.7% | 166,069 | 0.0% | 0.30% | -8.0% | |
| GRTS | Sell | GRITSTONE ONCOLOGY INC | $2,298,138 | -61.6% | 666,127 | -71.4% | 0.20% | -58.6% |
| New | PEAK BIO INC | $2,021,792 | – | 497,528 | +100.0% | 0.17% | – | |
| MIRM | MIRUM PHARMACEUTICALS INC | $1,261,650 | -7.2% | 64,700 | 0.0% | 0.11% | +0.9% | |
| ALDX | ALDEYRA THERAPEUTICS INC | $1,119,168 | +30.3% | 160,800 | 0.0% | 0.10% | +39.7% | |
| ALIMERA SCIENCES INC | $544,490 | -46.7% | 200,919 | 0.0% | 0.05% | -43.2% | ||
| TCMD | TACTILE SYSTEMS TECHNOLOGY I | $311,108 | +47.4% | 27,100 | 0.0% | 0.03% | +58.8% | |
| URGN | UROGEN PHARMA LTD | $217,315 | +6.5% | 24,500 | 0.0% | 0.02% | +18.8% | |
| GOSS | Sell | GOSSAMER BIO INC | $81,918 | -99.6% | 37,750 | -97.8% | 0.01% | -99.6% |
| Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -31,330 | -100.0% | -0.02% | – | |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -432,300 | -100.0% | -0.05% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -4,473,967 | -100.0% | -0.42% | – |
| ABMD | Exit | ABIOMED INC | $0 | – | -490,754 | -100.0% | -9.53% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Biomarin Pharmaceuticals, Inc | 42 | Q3 2023 | 16.6% |
| UNITED THERAPEUTICS CORP DEL | 42 | Q3 2023 | 15.3% |
| INSMED INC | 42 | Q3 2023 | 14.1% |
| STAAR Surgical Company | 42 | Q3 2023 | 11.8% |
| AMICUS THERAPEUTICS INC | 42 | Q3 2023 | 12.1% |
| VANDA PHARMACEUTICALS INC | 42 | Q3 2023 | 5.8% |
| PROTHENA CORP PLC | 42 | Q3 2023 | 9.1% |
| CYTOKINETICS INC | 40 | Q3 2023 | 0.4% |
| ALIGN TECHNOLOGY INC | 39 | Q3 2023 | 2.5% |
| ABIOMED INC | 38 | Q3 2022 | 17.1% |
View Palo Alto Investors LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ALIMERA SCIENCES INCSold out | April 03, 2023 | 0 | 0.0% |
| Epizyme, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| INSMED Inc | February 14, 2023 | 5,871,291 | 4.3% |
| Vanda Pharmaceuticals Inc. | February 14, 2023 | 1,087,064 | 1.4% |
| ALIMERA SCIENCES INC | February 14, 2022 | 802,423 | 11.6% |
| Clovis Oncology, Inc. | February 14, 2022 | 3,997,826 | 3.1% |
| STAAR SURGICAL CO | February 14, 2022 | 1,140,511 | 2.4% |
| Aimmune Therapeutics, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| AMAG PHARMACEUTICALS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| ALIMERA SCIENCES INC | February 14, 2020 | 802,424 | 16.2% |
View Palo Alto Investors LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-04-03 |
| 4 | 2023-03-28 |
View Palo Alto Investors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.